Effects of Co-application of Tiotropium Bromide and Traditional Chinese Medicine on Patients with Stable Chronic Obstructive Pulmonary Disease: a Muilticenter, Randomized, Controlled Trial Study

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2024 May 20

PMID 38765259

Authors

Ruilin Chen

Kaiwen Ni

Conghua Ji

Zhongda Liu

Yali Yu

Gang Liu

Junchao Yang

Zhen Wang

Affiliations

Soon will be listed here.

Abstract

Background: Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable, and treatable disease. Traditional Chinese Medicine (TCM) has shown promising potential in COPD treatment. and we conducted a multi-center RCT to evaluate the effectiveness of TCM-based therapy in stable COPD patients.

Methods: In this multicenter, double-blind RCT, a total of 200 patients were supposed to be assigned to either trial or control group randomly. Both groups received Tiotropium (18 μg) from month 0 to month 12. Trial group received additional TCM granules, while control group received a placebo from month 0 to month 6. Symptom assessment, total effective rate, lung function measurements, hospitalization rates, and quality of life were evaluated at month 0, month 6, and month 12. Adverse events were assessed at month 12.

Results: Of the initial 105 patients (aged 40-80) who completed the study, 51 were in trial group and 54 were in control group. At month 6, significant differences were observed between two groups in total effective rate ( = 0.020), sputum score ( = 0.047), changes in FVC% ( = 0.047) and FEV1 ( = 0.046). At month 12, significant differences were observed in sputum score ( = 0.020), FVC ( = 0.042), and change in FEV1 ( = 0.013). Compared to baseline, they both demonstrated improvements in symptoms, acute exacerbation, lung function, quality of life, and exercise tolerance.

Conclusion: TCM treatment effectively improved total effective rate, sputum symptom, FVC%, FEV1, and exhibited prolonged efficacy in improving sputum symptoms and FEV1 in stable COPD patients.https://www.chictr.org.cn/showproj.html?proj=6029 identifier ChiCTR-TRC-13003531.

References

Bikov A, Lange P, Anderson J, Brook R, Calverley P, Celli B . FEV is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease. Int J Chron Obstruct Pulmon Dis. 2020; 15:1135-1142. PMC: 7247606. DOI: 10.2147/COPD.S242809. View

Wedzicha J, Singh R, Mackay A . Acute COPD exacerbations. Clin Chest Med. 2014; 35(1):157-63. DOI: 10.1016/j.ccm.2013.11.001. View

Vos T, Flaxman A, Naghavi M, Lozano R, Michaud C, Ezzati M . Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2163-96. PMC: 6350784. DOI: 10.1016/S0140-6736(12)61729-2. View

Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V . Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2095-128. PMC: 10790329. DOI: 10.1016/S0140-6736(12)61728-0. View

Dajczman E, Wardini R, Kasymjanova G, Prefontaine D, Baltzan M, Wolkove N . Six minute walk distance is a predictor of survival in patients with chronic obstructive pulmonary disease undergoing pulmonary rehabilitation. Can Respir J. 2015; 22(4):225-9. PMC: 4530856. DOI: 10.1155/2015/280187. View

Lin L, Shan J, Xie T, Xu J, Shen C, Di L . Application of Traditional Chinese Medical Herbs in Prevention and Treatment of Respiratory Syncytial Virus. Evid Based Complement Alternat Med. 2016; 2016:6082729. PMC: 5027054. DOI: 10.1155/2016/6082729. View

Wang X, Liu Z . Prevention and treatment of viral respiratory infections by traditional Chinese herbs. Chin Med J (Engl). 2014; 127(7):1344-50. View

Jemal A, Ward E, Hao Y, Thun M . Trends in the leading causes of death in the United States, 1970-2002. JAMA. 2005; 294(10):1255-9. DOI: 10.1001/jama.294.10.1255. View

Zeng Y, Jiang F, Chen Y, Chen P, Cai S . Exercise assessments and trainings of pulmonary rehabilitation in COPD: a literature review. Int J Chron Obstruct Pulmon Dis. 2018; 13:2013-2023. PMC: 6027710. DOI: 10.2147/COPD.S167098. View

10.

Xiong C, Li Y, Zhuang G, Zeng Y, Wei H, Li C . Clinical efficacy and safety of Chinese herbal medicine versus placebo for the treatment of chronic obstructive pulmonary disease: A systematic review and meta-analysis. Complement Ther Med. 2021; 59:102691. DOI: 10.1016/j.ctim.2021.102691. View

11.

Keating G . Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease. Drugs. 2012; 72(2):273-300. DOI: 10.2165/11208620-000000000-00000. View

12.

Wang M, Li J, Li S, Xie Y . Effects of comprehensive therapy based on traditional Chinese medicine patterns on older patients with chronic obstructive pulmonary disease: a subgroup analysis from a four-center, randomized, controlled study. Front Med. 2014; 8(3):368-75. DOI: 10.1007/s11684-014-0360-0. View

13.

Ge H, Liu X, Gu W, Feng X, Zhang F, Han F . Distribution of COPD Comorbidities and Creation of Acute Exacerbation Risk Score: Results from SCICP. J Inflamm Res. 2021; 14:3335-3348. PMC: 8289369. DOI: 10.2147/JIR.S315600. View

14.

Carvalho-Jr L, Trimer R, Areas G, Caruso F, Zangrando K, Jurgensen S . COPD assessment test and FEV: do they predict oxygen uptake in COPD?. Int J Chron Obstruct Pulmon Dis. 2018; 13:3149-3156. PMC: 6183695. DOI: 10.2147/COPD.S167369. View

15.

Okutan O, Tas D, Demirer E, Kartaloglu Z . Evaluation of quality of life with the chronic obstructive pulmonary disease assessment test in chronic obstructive pulmonary disease and the effect of dyspnea on disease-specific quality of life in these patients. Yonsei Med J. 2013; 54(5):1214-9. PMC: 3743182. DOI: 10.3349/ymj.2013.54.5.1214. View

16.

Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C . Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018; 391(10131):1706-1717. DOI: 10.1016/S0140-6736(18)30841-9. View

17.

Huang X, Duan X, Wang K, Wu J, Zhang X . Shengmai injection as an adjunctive therapy for the treatment of chronic obstructive pulmonary disease: A systematic review and meta-analysis. Complement Ther Med. 2019; 43:140-147. DOI: 10.1016/j.ctim.2019.01.020. View

18.

Weiss S, Segal M, Sparrow D, Wager C . Relation of FEV1 and peripheral blood leukocyte count to total mortality. The Normative Aging Study. Am J Epidemiol. 1995; 142(5):493-8; discussion 499-503. DOI: 10.1093/oxfordjournals.aje.a117665. View

19.

Eklof J, Sorensen R, Ingebrigtsen T, Sivapalan P, Achir I, Boel J . Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22 053 patients. Clin Microbiol Infect. 2019; 26(2):227-234. DOI: 10.1016/j.cmi.2019.06.011. View

20.

Ritchie A, Wedzicha J . Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations. Clin Chest Med. 2020; 41(3):421-438. PMC: 7423341. DOI: 10.1016/j.ccm.2020.06.007. View